Biologics News
EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment of EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., NOVEMBER 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Takeda Pharmaceutical Limited Company as a specialty pharmacy provider for EXKIVITY™ (mobocertinib) for the...
WELIREG (belzutifan), FDA Approved, Available at Biologics by McKesson
CARY, N.C., August 20, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Merck & Co. as a specialty pharmacy provider for WELIREG™ (belzutifan) an inhibitor of hypoxia-inducible...
REZUROCK™ (belumosudil) Tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson
CARY, N.C., JULY 30, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, today announced that it has been selected by Kadmon (Nasdaq: KDMN) as a specialty pharmacy provider for REZUROCK™ (belumosudil) for the...
TRUSELTIQ (infigratinib), FDA Approved for Treatment of Cholangiocarcinoma, Available at Biologics by McKesson
CARY, N.C., June 21, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by QED Therapeutics, an affiliate of BridgeBio Pharma, Inc. (BridgeBio) and Helsinn Group, as a specialty pharmacy...
LUMAKRAS (sotorasib), FDA Approved for Treatment of KRAS G12C-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., June 11, 2021 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Amgen Oncology as a specialty pharmacy provider for LUMAKRASTM (sotorasib) for the treatment of patients with...
NULIBRY (fosdenopterin), First and Only FDA-Approved Therapy to Reduce the Risk of Mortality in Patients with Molybdenum Cofactor Deficiency Type A, Available Exclusively at Biologics by McKesson
CARY, N.C., April 19, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Origin Biosciences, Inc., an affiliate of BridgeBio Pharma, Inc. (BridgeBio), as the exclusive specialty pharmacy...
FOTIVDA (tivozanib), FDA Approved for Treatment of Relapsed/Refractory Advanced Renal Cell Carcinoma, Available at Biologics by McKesson
CARY, N.C., March 11, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by AVEO Oncology as a specialty pharmacy provider for FOTIVDA® (tivozanib) for the treatment of adult patients with...
ORGOVYX™ (relugolix), the First FDA-Approved Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer, Available at Biologics by McKesson
CARY, N.C., January 19, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Myovant Sciences as a specialty pharmacy provider for ORGOVYX™ (relugolix) for the treatment of advanced...
A Letter to Our Biopharma Clients About Organizational Changes
Valued Biopharma Partner, At Biologics by McKesson, we know that your complex, personalized therapies require customized support tailored to your unique needs. It is a privilege to serve as a partner to you in your product commercialization, collaborating to maximize...
GAVRETO™ (pralsetinib), FDA Approved for Treatment of Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., September 17, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Blueprint Medicines as a specialty pharmacy provider for GAVRETO™ (pralsetinib) for the treatment of adult...